Sort by
Refine Your Search
-
Listed
-
Category
-
Program
-
Field
-
we are committed to supporting the professional and career development of our postdocs and research staff. To help them thrive and achieve their ambitions, we have created a comprehensive range of
-
part of a wider programme of work to establish that membraneless organelles, biological liquid droplets, are effectively regions of organic solvent, suspended inside cells and that the properties of each
-
of a wider programme of work to establish that membraneless organelles, biological liquid droplets, are effectively regions of organic solvent, suspended inside cells and that the properties of each
-
2022, PMID: 36462505). The research will be conducted in a friendly and supportive atmosphere with access to outstanding facilities and within a vibrant postdoc community. The applicant should hold, or
-
for applications is 12:00 on Monday 7th July 2025. Interviews will be held as soon as possible thereafter. At the Dunn School we are committed to supporting the professional and career development of our postdocs
-
mentoring junior researchers and collaborate with faculty, DPhil students, and postdocs across engineering, computer science, government, and law disciplines. The role is full time 2 years fixed term
-
on single-agent settings. We are seeking a highly motivated postdoc to conduct research into this fast-moving area. Directions may include investigating quality evaluation methods for multi-agent systems
-
, project and continuous improvement teams, and suppliers to deliver solutions that align with university strategic priorities and Oxford’s Digital Transformation programme, which is reimagining the culture
-
. In addition to the NIHR funded post available, locally funded posts may also be awarded in parallel, subject to funding and assessment against the stated criteria for the role. Applicants should be
-
We are seeking an experienced Senior Postdoctoral Scientist to work with Professor Benoit Van den Eynde on a research programme developing new cancer vaccines based on a recombinant virus platform